Stryker Corporation

Stryker delivered 9% organic sales growth in the second quarter of 2026, with adjusted EPS rising 17.9% to $3.69, despite ongoing impacts from a cybersecurity incident and a Peripheral Vascular supply disruption. MedSurg & Neurotechnology grew 9.2% and Orthopaedics grew 8.6%, while international sales rose 8.9%, supported by markets including Australia, Germany, Canada, India and Brazil. Mako robotics surpassed 2.5 million procedures globally across 47 countries, with U.S. knee sales up 6.2% and Ortho Tech up 9.2% on robust installations. Management maintained full-year EPS guidance of $14.95-$15.10, though the Peripheral Vascular disruption is expected to drag organic growth by roughly 50-75 basis points until backorders normalize by the end of the third quarter. The Zacks Consensus Estimate for 2026 earnings has risen 3 cents to $15.02 per share over the past 60 days.

Stryker's Stryker Sales unit secured a $100 million contract modification from the US Defense Logistics Agency, a development that coincided with a 2.7% share price move. The contract news pushed Stryker higher, with the stock last closing at $327.70. The most followed narrative on Stryker currently points to a fair value of $386.80 per share, suggesting the stock is 15.3% undervalued. That valuation rests on a detailed view of procedure demand, margins, and how the business responds to hospital digitization over time. However, the narrative still relies on smooth regulatory approvals and stable procedure volumes, and setbacks in either could quickly challenge today's pricing optimism.

Stryker Corporation delivered 9% organic sales growth in the second quarter of 2026, with adjusted earnings up 17.9% to $3.69 per share and adjusted operating margin rising 170 basis points to 27.4%. MedSurg and Neurotechnology grew 9.2% organically while Orthopaedics increased 8.6%, and management narrowed its full-year organic sales growth outlook to 8.3% to 9.3%. The stock trades at 20.4 times forward earnings, below its five-year median of 26.0 times but above the Zacks sub-industry average of 16.9 times. Stryker ended the quarter with about $3.5 billion in cash and marketable securities, operating cash flow of $1.8 billion in the first half, and long-term debt down to $14.2 billion from $14.9 billion at year-end 2025. The company plans to resume share repurchases in the second half, while cyber remediation costs, vascular supply constraints, and acquisition integration keep execution risk elevated.

Stryker Corporation reported second-quarter 2026 sales of US$6,589 million and net income of US$1,276 million, with both basic and diluted EPS from continuing operations rising year-over-year. Management highlighted 9% organic sales growth, progress in recovering from a March cyberattack that disrupted operations, and a slight increase to full-year adjusted EPS guidance while planning to resume share repurchases. The company also announced the US commercial launch of the Mako RPS robotic power system for total knee replacement, alongside record Mako installations during the quarter. Persistent supply chain disruptions and backorders remain a risk, though the results suggest progress without a complete resolution.

Stryker reported second-quarter adjusted earnings of $3.69 per share, beating the Zacks Consensus Estimate of $3.46 per share and marking a 6.65% earnings surprise. Revenue came in at $6.59 billion, surpassing the consensus estimate by 0.48% and up from $6.02 billion a year ago. The company has topped consensus EPS estimates three times in the past four quarters. Stryker shares have added about 0.2% year to date, underperforming the S&P 500's 6.9% gain. The current Zacks Rank for the stock is #3 (Hold), with consensus estimates for the coming quarter at $3.73 per share on $6.72 billion in revenues.

DCLA managing partner Sarat Sethi expressed concern about massive AI capital expenditure plans at tech companies outside of Alphabet, while calling Alphabet a core portfolio holding because its diversified businesses give it many levers to toggle. He pointed to YouTube, Cloud, and Gemini as reasons Alphabet can adjust spending if returns on investment do not materialize. Sethi noted a divergence between hardware and software spending, with customers holding back on hardware while continuing to invest in software and security, citing IBM and SAP commentary. He said Microsoft faces particular scrutiny and must show return on investment faster than others, as the stock is already down double digits this year. Beyond tech, Sethi highlighted a rotation into high-quality, cash-flow-generating healthcare companies such as Stryker, Thermo Fisher, and Johnson & Johnson, noting the healthcare sector has shrunk to its smallest S&P 500 weighting ever.

The global robotic endoscopy devices market is projected to grow from $2.8 billion in 2025 to $6.5 billion by 2034, at a compound annual growth rate of approximately 10%, according to a report by DelveInsight. North America accounted for about 42% of global revenue in 2025, driven by widespread adoption of robotic-assisted surgical technologies and the presence of major players such as Intuitive Surgical, Medtronic, and Johnson & Johnson MedTech. The therapeutic robotic endoscopes category was the largest product segment, while the Asia-Pacific region is expected to see the highest growth due to aging populations and rising investments in robotic surgery. Key companies in the market include Intuitive Surgical, Johnson & Johnson MedTech, Medtronic, Olympus, Boston Scientific, FUJIFILM, Stryker, KARL STORZ, Asensus Surgical, and CMR Surgical. Recent developments include FDA clearance of Medtronic's Hugo system for urologic procedures in December 2025 and FDA 510(k) clearance of CMR Surgical's Versius Plus system for cholecystectomy.

Stryker announced the U.S. commercial launch of Mako RPS, a handheld robotic system for total knee replacement, on 16 July 2026. The system combines intraoperative planning with a robotically enabled saw and integrates with the Triathlon Total Knee System and Q Guidance platform. This launch extends the Mako ecosystem beyond robotic-arm systems into handheld robotics, potentially broadening adoption by matching robotic precision with familiar surgical workflows. The move reinforces Stryker's robotics catalyst but does not materially change near-term sensitivities around supply chain reliability and pricing pressures ahead of upcoming earnings.

The global surgical robots market is projected to grow from USD 13.69 billion in 2025 to USD 27.14 billion by 2030, at a compound annual growth rate of 14.7%, according to a new report by MarketsandMarkets. Growth is driven by increasing demand for minimally invasive surgeries, rising surgical volumes linked to chronic diseases and an aging population, and advances in robotic platforms, 3D visualization, AI-assisted navigation, and surgical instrumentation. Instruments and accessories represent the largest offering segment, general surgery is the largest application segment, and hospitals and clinics are the largest end-user segment. Asia Pacific is expected to be the fastest-growing regional market, with key players including Intuitive Surgical, Stryker Corporation, Medtronic, Smith+Nephew, and Zimmer Biomet.

Bell Global Equities Fund initiated a new position in Stryker Corporation during May 2026, citing the medical technology company's quality characteristics and an attractive entry point after a share-price decline. The fund highlighted Stryker's best-in-class management, decentralized operating model delivering organic revenue growth ahead of large-cap medtech peers, and durable competitive advantages anchored by the Mako robotics platform. The opportunity arose from a broader medtech de-rating and stock-specific weakness following a March cyberattack that temporarily disrupted operations, with shares falling to 52-week lows after the first-quarter result quantified the impact. Bell Global Equities Fund views the disruption as transitory, noting that underlying procedure volumes held steady, the order book remains elevated, and management maintained full-year organic sales growth guidance of 8 to 9.5 percent, with most delayed sales expected to be recouped over the remainder of 2026. The forward price-to-earnings multiple compressed to approximately 19 times from the 25 to 30 times range a year earlier, which the fund saw as a meaningful discount to history and relative to Stryker's quality and growth characteristics.

Healthcare robotics has reached mainstream scale, driven by an aging population, clinician shortages, and demand for minimally invasive procedures. Intuitive Surgical grew its da Vinci installed base 12% to 11,395 systems as of March 31, 2026, with procedures up about 16% year over year in the first quarter. Illumina and Stryker also exemplify the trend through lab automation and the Mako orthopedic system, respectively. The global healthcare robotics market is projected to rise from approximately $14.9 billion in 2023 to $57.0 billion by 2032, according to Johns Hopkins University. Among robotics ETFs, the Global X Robotics & Artificial Intelligence ETF holds Intuitive Surgical as its fifth position at 6.72% weight, the ROBO Global Robotics and Automation Index ETF holds Intuitive Surgical fourth at 1.77% and Illumina sixth at 1.69%, and the First Trust NASDAQ Artificial Intelligence and Robotics ETF holds Illumina fourth at 1.75%.

BTIG analyst Ryan Zimmerman reiterated a Buy rating and a $379 price target on Stryker Corp. on June 12. The bullish stance is driven by the company's Mako robotic system, which has become a leading platform for ambulatory surgery centers. Stryker is increasingly capitalizing on robotics in healthcare as young surgeons treat robotic systems as a baseline requirement and patients actively seek robotic-assisted procedures. The company's flexible contract structures, including volume-based agreements and walk-away clauses, are fueling robotics adoption by lowering financial risk barriers. Earlier, on May 26, Stryker launched its Pangea Plating System in Europe to treat a wide range of fracture patterns.

StockStory highlights Stryker as a cash-producing stock worth watching, while flagging Baker Hughes and Core Laboratories as facing challenges. Stryker's trailing 12-month free cash flow margin stands at 18.1%, with organic revenue growth averaging 9.2% over the past two years and EPS compounding at 12.2% annually over five years. Baker Hughes, with a free cash flow margin of 8.9%, has seen annual sales growth of 6.8% over five years and a gross margin of 22.1% that trails competitors. Core Laboratories, at a 3.5% free cash flow margin, posted muted 3.4% annual revenue growth over five years and a gross margin of 20.4%.

A bullish thesis on Stryker Corporation emphasizes its entrenched position in healthcare, strong brand loyalty, and recurring procedure-driven demand. The medical technology company reported first-quarter 2026 net sales of $6.0 billion, up 2.6% year over year, with organic sales growth of 2.4% and adjusted earnings per share of $2.60. Management maintained full-year guidance of 8.5% organic sales growth and adjusted earnings per share of $14.90 to $15.10 despite a late-quarter cyber incident. Stryker pays an annual dividend of $3.52 per share, yielding 1.17% with a 40.74% payout ratio, and has increased its dividend for 16 consecutive years. The thesis points to the company's diversified portfolio across orthopedics, surgical equipment, and neurotechnology as a foundation for long-term earnings and cash flow compounding.

Stryker Corporation announced the launch of TPX HD, a small bone power tool designed for demanding orthopaedic procedures including total joint revisions, minimally invasive surgery, and oral maxillofacial procedures. Mike Carlin, president of Stryker's Ortho Tech division, said revision surgeries are among the most demanding procedures, particularly when cutting metal, and that TPX HD was built for situations where visibility is limited, precision matters, and surgeons need a tool they can trust to perform. The device features a tapered attachment to improve visibility in confined spaces, a housing that helps reduce motor heat exposure at high operating speeds, and a shorter handpiece with an improved grip for better ergonomics. Stryker stated that TPX HD delivers up to 296% more torque and operates up to 40% faster than its TPX Micro Drill at high speed, and provides customizable controls through its CORE 2 Console and multiple specialized attachments.

Stryker Corp. introduced its Pangea Plating System to the European market on May 26, a hardware platform designed to treat various bone fracture patterns. The initial clinical case in Europe was handled by Prof. Alex Trompeter and his team at St. George's University Hospital in London. The system combines plates with dedicated instruments to provide versatile fixation options for upper and lower limb fractures. On June 12, Bank of America Securities lowered its price target on Stryker from $450 to $380 while maintaining a Buy rating, citing lower utilization levels and a conservative stance on 2027 forecasts for medical technology companies.

Stryker's free cash flow over the last twelve months reached approximately 137% of its reported net income, signaling a cash-generation strength that the market may be overlooking amid a recent cyberattack and a 17.6% stock decline over the past year. The company reiterated full-year organic net sales growth guidance of 8% to 9.5%, despite first-quarter organic sales growth of just 2.4%, and its robust cash conversion provides the financial fuel to absorb incident costs and fund operational recovery without sacrificing long-term investments. This cash-flow fortress supports the credibility of management's rebound target and suggests the underlying business is healthier than the recent disruption implies.